Analytical Pharmacology
分析药理学
基本信息
- 批准号:8450535
- 负责人:
- 金额:$ 7.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-08-01 至 2017-11-30
- 项目状态:已结题
- 来源:
- 关键词:BiologicalBiological MarkersCancer CenterCancer Center Support GrantCategoriesClinicalCollaborationsComplexComputer softwareConsultationsCore FacilityCorrelative StudyDataData AnalysesDetectionDevelopmentDiseaseDrug KineticsEquipmentFluorescenceGasesGoalsHigh Pressure Liquid ChromatographyHuman ResourcesInstructionInvestigationMalignant NeoplasmsManuscriptsMetalsMethodsMissionModelingNatural graphitePharmaceutical PreparationsPharmacologyPreparationProcessProtocols documentationReportingResearchResearch DesignResearch Project GrantsRunningSamplingScientistServicesSolventsSystemTissue SampleValidationWaterWritinganalytical methodassay developmentdata acquisitiondesignfallsfightingflexibilityinnovationinstrumentliquid chromatography mass spectrometrymass spectrometermeetingspre-clinicalprograms
项目摘要
PROJECT SUMMARY (See instructions):
The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research among COHCCC basic scientists and clinicians by providing a wide range of analytical and consultative services. APCF assists with the design and conduct of pharmacokinetic studies for clinical and preclinical investigations. Primary services provided are: 1) quantitative assay development and sample analysis (LCMS/ MS, GC/MS, AAS, and HPLC) of drugs, biomarkers, and related compounds, and 2) study design and expert analysis of pharmacokinetic and metabolite data. APCF is located in the Shapiro Building and all of the major analytical equipment is consolidated into a contiguous suite of rooms. The most heavily utilized major equipment within the core are the 3 LC-MS/MS instruments, including a Micromass Quattro Ultima triple quad, a Waters Quattro Premier XE triple quad, and an AB Sciex QTRAP 5500. Each of these instruments includes different HPLC components with unique features that provide greater flexibility, and each of the systems provides state-of-the-art selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass and Waters systems are coordinated through separate MassLynx-NT Workstations running MassLynx and QuanLynx software. MetaboLynx software is also available for the Quattro Premier XE to aid in metabolite identification. Instrument control and data analysis for the QTRAP 5500 is performed on a dedicated workstation running Analyst software. Additional core equipment includes: a Shimadzu Model QP-5000 El gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software; a Perkin Elmer AAnalyst 300 AAS with an HGA 800 graphite furnace for determination of metals and metal containing compounds; and three complete HPLC systems consisting of six solvent delivery modules (4 Shimadzu LC-IOA's, 2 Shimadzu LClOAD's). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 51 OOA and 5200A), and photodiode array (Waters Acquity PDA) detection systems. Between July 1, 2010 and June 30, 2011, a total of 13 analytical methods were developed or re-initiated, 2657 samples analyzed, and 907 clinical samples processed during the reporting period.
项目总结(见说明):
分析药理学核心设施(APCF)通过提供广泛的分析和咨询服务,鼓励和促进COHCCC基础科学家和临床医生之间的合作研究。APCF协助设计和实施临床和临床前研究的药代动力学研究。提供的主要服务包括:1)药物、生物标志物和相关化合物的定量分析开发和样品分析(LC MS/MS、GC/MS、AAS和HPLC),以及2)药代动力学和代谢物数据的研究设计和专家分析。APCF位于夏皮罗大楼,所有主要的分析设备都整合到一个连续的房间套间中。核心内使用率最高的主要设备是3台LC-MS/MS仪器,包括MicroBulk Quattro Ultima三重四元组、Waters Quattro Premier XE三重四元组和AB Sciex QTRAP 5500。这些仪器中的每一个都包括具有独特功能的不同的高效液相组件,提供了更大的灵活性,并且每个系统都为复杂生物基质中的分析物提供了最先进的选择性和灵敏度。MicroMassand Waters系统的仪器控制和数据采集通过运行MassLynx和QuanLynx软件的不同MassLynx-NT工作站进行协调。Quattro Premier XE也可使用MetbraLynx软件来帮助识别代谢物。QTRAP 5500的仪器控制和数据分析是在运行分析软件的专用工作站上执行的。其他核心设备包括:岛津QP-5000型EL气相色谱仪/质谱仪,直接连接到运行Class-5000软件的专用PC;Perkin Elmer AAnalyst 300 AAS,带HGA 800石墨炉,用于测定金属和含金属化合物;以及三套完整的高效液相系统,由六个溶剂输送模块组成(4个岛津LC-IOA,2个岛津LClOAD)。高效液相检测能力涵盖了目前可用的各种方法,包括UV/VIS(岛津SPD-10AV)、荧光(岛津RF-10A)、电化学(ESA型号5100A和5200A)和光电二极管阵列(Waters Acquity PDA)检测系统。在2010年7月1日至2011年6月30日期间,共开发或重新启动了13种分析方法,分析了2657个样本,并在报告所述期间处理了907个临床样本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL A FRIEDMAN其他文献
MICHAEL A FRIEDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL A FRIEDMAN', 18)}}的其他基金
EMOTION, SOCIAL SUPPORT & THE COURSE OF MAJOR DEPRESSION
情感、社会支持
- 批准号:
2708739 - 财政年份:1999
- 资助金额:
$ 7.34万 - 项目类别:
相似海外基金
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10490338 - 财政年份:2021
- 资助金额:
$ 7.34万 - 项目类别:
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10353104 - 财政年份:2021
- 资助金额:
$ 7.34万 - 项目类别:
Investigating pollution dynamics of swimming pool waters by means of chemical and biological markers
利用化学和生物标记物研究游泳池水体的污染动态
- 批准号:
21K04320 - 财政年份:2021
- 资助金额:
$ 7.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10688286 - 财政年份:2021
- 资助金额:
$ 7.34万 - 项目类别:
Novel biological markers for immunotherapy and comprehensive genetic analysis in thymic carcinoma
用于胸腺癌免疫治疗和综合遗传分析的新型生物标志物
- 批准号:
20K17755 - 财政年份:2020
- 资助金额:
$ 7.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10578649 - 财政年份:2019
- 资助金额:
$ 7.34万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10295141 - 财政年份:2019
- 资助金额:
$ 7.34万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10041708 - 财政年份:2019
- 资助金额:
$ 7.34万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
9776149 - 财政年份:2019
- 资助金额:
$ 7.34万 - 项目类别:
Combining biological and non-biological markers to develop a model predictive of treatment response for individuals with depression
结合生物和非生物标志物来开发预测抑郁症患者治疗反应的模型
- 批准号:
2063934 - 财政年份:2018
- 资助金额:
$ 7.34万 - 项目类别:
Studentship














{{item.name}}会员




